AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06020781
Drug: bupivacaine and dexmedetomidine.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
Trial: NCT06020781
Drug: bupivacaine only
RxNorm normalized name: Bupivacaine only product
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
Trial: NCT06020781
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
Trial: NCT06268964
Drug: Trimebutine
RxNorm normalized name: trimebutine
DrugBank: Trimebutine (DB09089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.
Trial: NCT05287724
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,500 mg twice daily for seven days
Trial: NCT04563195
Drug: tibulizumab (LY3090106)
RxNorm normalized name: ibalizumab
DrugBank: Tibulizumab (DB14848)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subcutaneous injections of 300mg every 2 weeks over a period of 12 weeks
Trial: NCT04994522
Drug: Belzutifan
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three 40 mg tablets given as a single oral 120 mg dose.
Trial: NCT05476783
Drug: TB006
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Clear to slightly opalescent, sterile solution for injection
Trial: NCT05421013
Drug: STP705
RxNorm normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
DrugBank: Cotsiranib (DB18404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STP705 targets TGFB-1 and COX-2 mRNA respectively.
Trial: NCT06128369
Drug: Dexamethasone Ophthalmic Suspension
RxNorm normalized name: Dexamethasone Ophthalmic Suspension
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).
Trial: NCT06674525
Drug: 626
RxNorm normalized name: R1626
DrugBank: R1626 (DB05060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection
Trial: NCT04617600
Drug: MTA
RxNorm normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survival rate using MTA in cariously exposed vital primary molars
Trial: NCT04617600
Drug: TheraCal PT
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survival rate using TheraCal PT in cariously exposed vital primary molars
Trial: NCT05612594
Drug: Bexagliflozin 20 mg
RxNorm normalized name: bexagliflozin 20 MG
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg once daily
Trial: NCT04882358
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment with a standard dose of SGLT-2 inhibitor
Trial: NCT06725368
Drug: PCC
RxNorm normalized name: PCC
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles. 1 cycle lasts 1 week. The Carboplatin + Paclitaxel administration schedule 3 weeks out of 4, with weekly Cetuximab is authorized.~After 16 cycles: maintenance with Cetuximab 500 mg/m2 every 14 days until unacceptable toxicity or progression or death.
Trial: NCT06537674
Drug: Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection
Trial: NCT05396144
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide will be administered by face or nasal mask to be inhaled by the patient
Trial: NCT05630677
Drug: Rabeprazole, Delayed-release tablet
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
Trial: NCT05630677
Drug: Rabeprazole, Delayed-release tablet
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
Trial: NCT05457400
Drug: ENSO 16
RxNorm normalized name: Ensovibep
DrugBank: Ensovibep (DB19078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g ENSO 16 dissolved in Water
Trial: NCT04901104
Drug: Thymosin Alpha1
RxNorm normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug interventions have been done in previous clinical studies
Trial: NCT05652530
Drug: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing. Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion.
Trial: NCT04713956
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF was administered at 5 ug/kg/day on days-17 to -10. When white blood cell is more than 20G/L, stop using G-CSF.
Trial: NCT04713956
Drug: Decitabine (DAC)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine was administered at 20mg/m2/day on days -14 to -10.
Trial: NCT04713956
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4 in G-CSF+DAC+BUCY group, and it was administered at 3.2 mg/kg/day on days -6 to -3 in G-CSF+DAC +BF group .
Trial: NCT04713956
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine was administered at 30 mg/m2/day on days -7 to -3.
Trial: NCT06082856
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
Trial: NCT05113537
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given Orally
Trial: NCT05113537
Drug: Lutetium Lu 177-PSMA-617
RxNorm normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06273397
Drug: Acetazolamide 250 MG
RxNorm normalized name: acetazolamide 250 MG
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Trial: NCT06273397
Drug: Metolazone 2.5 MG
RxNorm normalized name: metolazone 2.5 MG
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Trial: NCT05987397
Drug: idebenone 30 mg for 14 days
RxNorm normalized name: idebenone 30 MG
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
Trial: NCT05987397
Drug: idebenone 30 mg for 3 months
RxNorm normalized name: idebenone 30 MG
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
Trial: NCT06273397
Drug: Furosemide Injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
Trial: NCT06339619
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg ivgtt D1 Q3W
Trial: NCT06339619
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg PO QD
Trial: NCT06339619
Drug: Tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
Trial: NCT04522596
Drug: Umeclidinium/vilanterol
RxNorm normalized name: UMECLIDINIUM/VILANTEROL
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Umeclidinium/vilanterol 55/22 μg inhaled once a day
Trial: NCT05671913
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment arm
Trial: NCT04921007
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
Trial: NCT01728051
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05398510
Drug: SHR-2010 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
Trial: NCT05946798
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Trial: NCT05591079
Drug: CS0159 (Linafexor)
RxNorm normalized name: Linafexor
DrugBank: Linafexor (DB18031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QD
Trial: NCT06409637
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib: For patients with a body weight \<60 kg, the recommended daily dose of lenvatinib is 8 mg (2 capsules of 4 mg each), once daily; for patients with a body weight ≥60 kg, the recommended daily dose of lenvatinib is 12 mg (3 capsules of 4 mg each), once daily. Treatment should be continued until disease progression, intolerable adverse effects, or the end of the study.
Trial: NCT06047262
Drug: Dapansutrile
RxNorm normalized name: Dapansutrile
DrugBank: Dapansutrile (DB16130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive investigational product.
Trial: NCT04799249
Drug: Trilaciclib
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
Trial: NCT04799249
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
Trial: NCT04799249
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
Trial: NCT04996251
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy
Trial: NCT05487586
Drug: ceftazidime avibactam group
RxNorm normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-Interventional Study
Trial: NCT05193318
Drug: Ketamine-assisted psychotherapy
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 8 weekly intramuscular injections of ketamine hydrochloride starting at 0.5 mg/kg and increasing to a maximum dose of 1.5 mg/kg or a total dose of 60 mg, whichever is lower. Ketamine administration will be accompanied by psychotherapy before, after and during the session.
Trial: NCT04879966
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Trial: NCT05037032
Drug: Naltrexone Pill
RxNorm normalized name: naltrexone Pill
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg PO one-time only
Trial: NCT05996133
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.25% bupivacaine
Trial: NCT05996133
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mL (5 mg) preservative-free dexamethasone
Trial: NCT05699824
Drug: Carvedilol Day2
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol will be initiated on day 2, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
Trial: NCT05699824
Drug: Carvedilol Day6
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol will be initiated on day 6, at a dose of 3.125mg twice a day (6.25mg/day), along with standard management as per institutional protocol for AVB.
Trial: NCT03549819
Drug: Cannabidiol (CBD) Oil Capsules
RxNorm normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
Trial: NCT03549819
Drug: Sunflower Lecithin Oil in Capsule
RxNorm normalized name: sunflower lecithin
DrugBank: Lecithin (DB15834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
Trial: NCT05104905
Drug: bexmarilimab
RxNorm normalized name: Bexmarilimab
DrugBank: Bexmarilimab (DB16383)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single neoadjuvant dose will be administered prior to surgery.
Trial: NCT00028132
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002111
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03874455
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Trial: NCT05041062
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
Trial: NCT05041062
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
Trial: NCT06393972
Drug: Tofacitinib 5 MG BID
RxNorm normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib 5 MG BID
Trial: NCT05351905
Drug: CBD oil ( MPL-001)
RxNorm normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Trial: NCT05351905
Drug: CDB+THC oil (MPL-005)
RxNorm normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Trial: NCT00005024
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005024
Drug: granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05185999
Drug: Icodextrin/Dextrose
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single 8 hour dwell of a 500mL intraperitoneal sodium-free 30% Icodextrin / 10% Dextrose solution
Trial: NCT06293547
Drug: Silver Diamine Fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
Trial: NCT05203172
Drug: Encorafenib only Treatment
RxNorm normalized name: Encorafenib only product
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent Study.
Trial: NCT05203172
Drug: Encorafenib & Binimetinib Treatment
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 45 mg BID schedule, both orally as a flat fixed dose. Cetuximab will be administered at either 400 mg/m2 or 500 mg/m2 IV every 2 weeks on Days 1 and 15 of every cycle.